nach oben

Erschienen in:

23.06.2022 | Adipositas | Zertifizierte Fortbildung

Hintergrund und Therapiemöglichkeiten

Adipositas und Herzinsuffizienz

verfasst von: Karl-Patrik Kresoja, Dr. med., Prof. Dr. med. Holger Thiele, Philipp Lurz, Prof. Dr. med.

Erschienen in: CardioVasc | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

Mehr als jeder zehnte Erwachsene ist von Adipositas betroffen. Adipositas kann sowohl über direkte als auch indirekte Effekte zur Entstehung einer Herzinsuffizienz beitragen und die Prognose beeinflussen. Welche Mechanismen verantwortlich sind und welche therapeutischen Möglichkeiten sich daraus ergeben, wird in diesem Artikel erläutert. …

Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128

World Health Organisation. [WHO Fact Sheet] Obesity and overweight. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight

Loos RJF. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab. 2012;26:211-26

Sommer I, Griebler U, Mahlknecht P et al. Socioeconomic inequalities in non-communicable diseases and their risk factors: an overview of systematic reviews. BMC Public Health. 2015;15:914

Gebreab SZ, Vandeleur CL, Rudaz D et al. Psychosocial Stress Over the Lifespan, Psychological Factors, and Cardiometabolic Risk in the Community. Psychosom Med. 2018;80:628-39

Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science. 2016;354:69-73

Flegal KM, Kruszon-Moran D, Carroll MD et al. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA. 2016;315:2284-91

Afshin A, Forouzanfar MH, Reitsma MB et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13-27

Lavie CJ, Sharma A, Alpert MA et al. Update on Obesity and Obesity Paradox in Heart Failure. Prog Cardiovasc Dis. 2016;58:393-400

10.

Hamzeh N, Ghadimi F, Farzaneh R, Hosseini SK. Obesity, Heart Failure, and Obesity Paradox. J Tehran Heart Cent. 2017;12:1-5

11.

Alpert MA, Lavie CJ, Agrawal H et al. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res. 2014;164:345-56

12.

Powell-Wiley TM, Poirier P, Burke LE et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143:e984-e1010

13.

Kresoja K-P, Rommel K-P, Wachter R et al. Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23:1633-44

14.

Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898-918

15.

Csige I, Ujvárosy D, Szabó Z et al. The Impact of Obesity on the Cardiovascular System. J Diabetes Res. 2018;2018:3407306

16.

Kresoja KP, Rommel KP, Fengler K et al. Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2021;14:e007421

17.

Lurz P, Kresoja KP, Rommel KP et al. Changes in Stroke Volume After Renal Denervation: Insight From Cardiac Magnetic Resonance Imaging. Hypertension. 2020;75:707-13

18.

Elagizi A, Kachur S, Lavie CJ et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis. 2018;61:142-50

19.

Lavie CJ, Laddu D, Arena R et al. Reprint of: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:3027-52

20.

Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-71

21.

VanWagner LB, Wilcox JE, Colangelo LA et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015;62:773-83

22.

Haykowsky MJ, Brubaker PH, Morgan TM et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci. 2013;68:968-75

23.

Mafort TT, Rufino R, Costa CH, Lopes AJ. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. 2016;11:28

24.

Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-13

25.

Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-77

26.

Calle EE, Thun MJ, Petrelli JM et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097-105

27.

Pandey A, LaMonte M, Klein L et al. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. J Am Coll Cardiol. 2017;69:1129-42

28.

Kresoja KP, Rommel KP, Thiele H, Lurz P. Adipositas und HFpEF - Henne oder Ei? Adipositas - Ursachen, Folgeerkrankungen, Therapie. 2021;15:21-7

29.

Obokata M, Reddy YNV, Pislaru SV et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136:6-19

30.

Kitzman DW, Lam CSP. Obese Heart Failure With Preserved Ejection Fraction Phenotype: From Pariah to Central Player. Circulation. 2017;136:20-3

31.

Bozkurt B, Aguilar D, Deswal A et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134:e535-e578

32.

Horwich TB, Fonarow GC, Clark AL. Obesity and the Obesity Paradox in Heart Failure. Prog Cardiovasc Dis. 2018;61:151-6

33.

Standeven KF, Hess K, Carter AM et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35:1031-40

34.

Martin J, Bergeron S, Pibarot P et al. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Can J Cardiol. 2013;29:969-75

35.

Rodriguez Flores M, Aguilar Salinas C, Piché ME et al. Effect of bariatric surgery on heart failure. Expert Rev Cardiovasc Ther. 2017;15:567-79

36.

Lavie CJ, Mehra MR, Ventura HO. Body Composition and Advanced Heart Failure Therapy: Weighing the Options and Outcomes. JACC Heart Fail. 2016;4:769-71

37.

Pandey A, Patel KV, Vaduganathan M et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2018;6:975-82

38.

Lavie CJ, Cahalin LP, Chase P et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251-8

39.

Pandey A, Patel KV, Lavie CJ. Obesity, Central Adiposity, and Fitness: Understanding the Obesity Paradox in the Context of Other Cardiometabolic Parameters. Mayo Clin Proc. 2018;93:676-8

40.

Beck-da-Silva L, Higginson L, Fraser M et al. Effect of Orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail. 2005;11:118-23

41.

Jorsal A, Kistorp C, Holmager P et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69-77

42.

Margulies KB, Hernandez AF, Redfield MM et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316:500-8

43.

Ghosh RK, Ghosh GC, Gupta M et al. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure. Am J Cardiol. 2019;124:1790-6

44.

Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-24

45.

Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451-61

46.

Borg CM, Le Roux CW, Ghatei MA et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210-5

47.

Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227-35

48.

Garza CA, Pellikka PA, Somers VK et al. Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for morbid obesity. Am J Cardiol. 2010;105:550-6

49.

Leichman JG, Wilson EB, Scarborough T et al. Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med. 2008;121:966-73

50.

Johnson BL, Blackhurst DW, Latham BB et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216:545-56; discussion 556-8

51.

McCloskey CA, Ramani GV, Mathier MA et al. Bariatric surgery improves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg Obes Relat Dis. 2007;3:503-7

52.

Klein S, Fontana L, Young VL et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-57

Titel: Hintergrund und Therapiemöglichkeiten
Adipositas und Herzinsuffizienz
verfasst von: Karl-Patrik Kresoja, Dr. med.
Prof. Dr. med. Holger Thiele
Philipp Lurz, Prof. Dr. med.
Publikationsdatum: 23.06.2022
Verlag: Springer Medizin
Schlagwörter: Adipositas
Adipositas
Herzinsuffizienz
Bariatrische Chirurgie
Bariatrische Chirurgie
Erschienen in: CardioVasc / Ausgabe 3/2022
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-022-3673-y

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Therapie der chronischen Herzinsuffizienz bei Diabetes

Hypertonie: Sargnagel für die diastolische J-Kurve

So sollten Wearables zur Arrhythmie-Detektion eingesetzt werden

Kabellose Herzschrittmacher im Aufwind

Nächtlicher Hypertonus

Adipositas und Gestationsdiabetes in der Schwangerschaft